SERPING1 and hereditary angioedema: It is not believed that HAE-FXII or HAE-C1INH involve tissue kallikrein; rather, plasma kallikrein is a validated target for the development of prophylactic drugs such as lanadelumab, berotralstat and ecallantide for the prophylaxis of classical HAE attacks (23, 24).